Physician profile
Syed A Moeed
NPI 1255371498
$5,780.60
in general payments reported to CMS, 2019-2025
26 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $795 · 2021: $1,217 · 2022: $1,065 · 2023: $827 · 2024: $677 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.13 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $996.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $955.77 | 2019-2025 | |
| Abbvie INC. | $625.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $583.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $534.02 | 2021-2024 | |
| Novo Nordisk INC | $338.98 | 2019-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $207.76 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $201.24 | 2021 | |
| Allergan, INC. | $132.32 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $130.61 | 2019-2024 | Rexulti |
| Amgen INC. | $114.69 | 2019-2024 | Krystexxa |
| Exact Sciences Corporation | $112.71 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $103.47 | 2019 | |
| Glaxosmithkline, LLC. | $91.32 | 2021-2025 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $80.77 | 2021-2024 | Eliquis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.36 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.01 | 2019 | |
| Inspire Medical Systems, INC. | $73.16 | 2023-2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $73.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $70.46 | 2020 | |
| Watermark Medical, INC. | $46.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $43.68 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.85 | 2021 | |
| Philips North America LLC | $36.89 | 2020-2023 | |
| Global Blood Therapeutics, INC. | $18.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Moeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.